ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Biopharma EHS Podcast Episode No. 16"
Episode Synopsis
In this podcast, Dean M. Calhoun, CIH and Joe Nieusma, Ph.D. of Affygility Solutions discuss Category 4 and Category 5 Potent Compounds - Understanding the Risks.
Items covered include:
Review of the last podcast
What factors go into determining an active pharmaceutical ingredients as a Category 4 or Category 5 potent compound
We provide examples of Category 4 and Category 5 potent compounds
Review upcoming events and happenings related to environmental, health and safety in the biotechnology, pharmaceutical, and medical device industry.
If you have any questions please contact Affygility Solutions at 303-884-3028 or visit the Affygility Solutions website.
Items covered include:
Review of the last podcast
What factors go into determining an active pharmaceutical ingredients as a Category 4 or Category 5 potent compound
We provide examples of Category 4 and Category 5 potent compounds
Review upcoming events and happenings related to environmental, health and safety in the biotechnology, pharmaceutical, and medical device industry.
If you have any questions please contact Affygility Solutions at 303-884-3028 or visit the Affygility Solutions website.
More episodes of the podcast Biopharma EHS
Biopharma EH&S podcast episode #27
03/02/2020
Biopharma EHS Podcast Episode 26
03/01/2020
Jul 20 2017 Flashing Briefing
20/07/2017
BioPharma EHS Podcast Episode 25
06/05/2017
Biopharma EHS Podcast Episode #24
17/01/2016
Biopharma EHS Podcast Episode #23
19/11/2014
Risk-MaPP, ADEs, and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities
24/10/2014
Biopharma EHS Podcast Episode No. 20
14/07/2013
In God we trust